The second general assembly of the project was held on 23 November in Barcelona to follow up and define the next steps
The 17 organisations that constitute SPIOMET4HEALTH met on Wednesday 23 November in Barcelona (Spain) and online. The second General Assembly of the project was hosted by Fundació Sant Joan de Déu (FSJD)/ Hospital Sant Joan de Déu (HSJD) as project coordinators, to discuss with the whole consortium the progress made and to define the next steps.
The SPIOMET4HEALTH consortium is formed by key research groups working on PCOS across Europe from 9 different countries (ES, BE, DE, AT, DK, NO, IT, TR, IE): Katholieke Universiteit Leuven, Fundació Institut D’investigacio Biomedica De Girona Doctor Josep Trueta, Private Universitaet Witten/Herdecke Ggmbh, Medizinische Universitat Graz, Region Syddanmark, Norges Teknisk-Naturvitenskapelige Universitet, Alma Mater Studiorum – Universita Di Bologna, Istanbul Universitesi, Optimapharm, Laboratorio Reig Jofre SA, Complutense University of Madrid, Outcomes’10 SL, European Institute of Women’s, Make Mothers Matter EU Delegation, Asphalion SL and Zabala Innovation.
The project was launched in April 2021 and is funded by the European Union’s Horizon 2020 Framework Programme for Research and Innovation (agreement no. 899671) and will run until 2026.
SPIOMET4HEALTH aims to provide a novel treatment for adolescent and young adult women with Polycystic Ovary Syndrome (PCOS). The challenge is to test the new treatment proposed by SPIOMET4HEALTH in phase II clinical trials in different centres in Spain, Austria, Norway, Italy, Denmark and Turkey.
SPIOMET4HEALTH’s clinical trial progress
The partners of the project consortium met at the second General Assembly with the main objective of performing a follow-up of the project, showing the main advances made during the first year and a half. The consortium focused on defining the next steps to achieve the success of the clinical trial in the different European centres.
The day’s programme started with a welcome by Dr Lourdes Ibáñez, coordinator (HSJD) of the SPIOMET4HEALTH project. The Work Package (WP) leaders and clinical centres then gave presentations on their latest status and progress.
The project group is at the moment focused on recruiting patients for the clinical trial. SPIOMET4HEALTH looks for participants with PCOS between 12 and 24 years old, irregular menstrual periods and excess body hair in Spain (Barcelona and Girona), Austria (Graz), Norway (Trondheim), Italy (Bologna), Denmark (Odense) and Turkey (Istanbul).
The meeting also improved strategies and procedures to ensure proper interaction between all professionals involved in the project. The SPIOMET4HEALTH partners held fruitful discussions it the second General Assembly. All partners were thanked for the great effort they are making and encouraged to continue working to achieve the ambitious goals of the project.